Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
!_Professional_! schreef op 12 maart 2019 14:40 :
"In the short run, the market is a voting machine but in the long run it is a weighing machine"? (Benjamin Graham)
En er is weer een nieuwe haha, praat ook engels apparently! TERRIRBBBLEBNELBLEBLEBE STOCK!!@!!!E@#@$@!
Lunten schreef op 12 maart 2019 14:43 :
[...]
Omgezette opties? Zegt u dat iets?
Kijk eens naar het aantal effectieve aandelen van de CEO de laatste jaren.
hahahaha NETTO VERKOPEN - er is rekening gehouden met uitoefenen opties, dan kan je hier zelf toch ook wel uit opmaken?
T’is wat, stijgt de koers, komt er out of the bleu een !Professional! ten tonele.:-)
Wegertje schreef op 12 maart 2019 14:46 :
T’is wat, stijgt de koers, komt er out of the bleu een !Professional! ten tonele.:-)
En een heleboel mensen die er nodeloos op reageren.
Ik beloof je dat ik na vandaag deze maand niet meer actief ben op dit forum. Elke maand een dagje berichten plaatsen
Zalig zijn de simpelen van geest
[Modbreak IEX: Gelieve inhoudelijk te reageren, bericht is bij dezen verwijderd.]
Pharming is hot schreef op 12 maart 2019 14:34 :
Om het vuurtje nog maar eens op te stoken qua evt overnames leuk om te lezen, weet alleen niet of dit een betrouwbaar iets is
www.spglobal.com/marketintelligence/e... DIKKE VETTE AB!
!_Professional_! schreef op 12 maart 2019 14:38 :
Just read the facts...
Is there a difference between what management is telling and what management is doing?
www.trivano.com/aandeel/pharming.450.... Uit de kwartaal- en jaarrapporten: Het volledig verwaterde aantal aandelen op 25 oktober 2018 bedraagt 657.578.717 Nu: het volledig verwaterde aantal aandelen is 663,472,724 Die opties moeten op 31 januari gewoon zijn toegevoegd... anders kan het totaal aantal aandelen bij volledige verwatering niet zoveel toenemen.
Geef mij maar De Monitor dan.
Inhoudelijke reacties zou ik zeer waarderen! Company is paying First Berlin to write research - Mngnt is massively selling stock - Very Aggressive financing in place (and company is even proposing approval to get room for a share buyback. IN my opinion for one reason, squeeze out the last penny for themselves - Net Cash balance worsened yoy 2018 vs 2017 if you correct for milestone payment in Q19 and increase in liabilities - I wonder if accountant is willing to provide a going concern opinion - The 'profit' in 2018 is from a very low quality (no cash generation + recognizing deferred tax asset of EUR 25m.6, while the net profit was EUR 25m --> complete JOKE ** Buy recco by first Berlin.... Interestingly, there is a disclaimer in the report stating First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer.** - Compared to competing therapies lanadelumab (Shire) and Haegarda (CSL), Ruconest scores last on efficacy, convenience in dosing schedule, and mode of administration or price - Lanadelumab's great commercial advantage is based on a low volume SC injection to be administered once every two weeks, or once every to four weeks if the patient is well-controlled for more than 6 months. In contrast, to twice weekly with Cinryze, Haegarda, and Ruconest. - FDA requested September 21st an additional trial for Ruconest's prophylaxis supplemental biological license application (sBLA) to evaluate the effectiveness. If rejected (not priced into Kempen's EUR 0.4/shr price target), peak sales of Ruconest are exp to nearly half to ~USD 200m vs USD 340m. - On top of that, another competitor in November 12th, - Klavissta announced HAE drug ready to go to mkt in 2023 instead of 2020 Also see Pharming's prophylactic hereditary angioedema strategy under discussion: www.pharmaceutical-technology.com/com... -) While management keeps on marketing this stock on retail conferences, it looks like except Kempen, it is paying other brokers for research coverage, while management itself is aggressively selling out, see below, source www.trivano.com/aandeel/pharming.450.... - The company uses extremely expensive financing and gave everything it owns as collateral (its latest annual report) Summary: EUR 90m loan, EUR 10m fees, 12% interest and everything it owns as collateral..... source annual report 2017 Under the terms and conditions of the new debt facility, the Lenders provided an amount of US$100 million €91.3 million) secured senior debt funding against 48 months promissory notes with interest of the sum of (i) the Applicable Margin of 11% plus (ii) the greater of (x) One-Month LIBOR and (y) 1.00%. Repayment of the loan and starts in September 2018 in quarterly installments. The Company has the option to prepay the loan before its maturity date. As further consideration for the facility, the Lenders received a 4% warrant coverage (9,174,372 warrants) with a strike price of €0.455 representing the closing price of Pharming shares immediately prior to the closing date, plus a 2.5% commitment fee of the principal sum and an assignment fee on the maturity date of US$3.7 million. The warrant strike price was increased from the maximum originally announced because of the increasing price of Pharming shares prior to closing of the loan. Other facility fees of €1.1 million have been deferred from the original loans. The warrants have been separated from the loan and recognized in Equity. The Company, and its subsidiaries, have pledged all receivables, movable assets and intellectual property rights as security to the new lenders, in the same way as those assets were pledged to the original lenders. Inhoudelijke reacties zou ik zeer waarderen! --> waarom zit ik ernaast?
[Modbreak IEX: Gelieve op de inhoud van uw berichten te letten, bericht is bij dezen verwijderd.]
Wegertje schreef op 12 maart 2019 14:46 :
T’is wat, stijgt de koers, komt er out of the bleu een !Professional! ten tonele.:-)
die stijging had hij nog niet verwacht ,nu wil hij nog snel goedkoop coveren.
dimitri00 schreef op 12 maart 2019 13:48 :
[...]
dan moet iemand mij toch eens haarfijn uitleggen waarom pharming zo'n fantastisch overname kandidaat is , want ik zie het niet
met nieuw kapitaal een versnelling in de pipeline tot stand brengen hetgeen miljarden zal opleveren
BassieNL schreef op 12 maart 2019 14:48 :
[...]
Het volledig verwaterde aantal aandelen op 25 oktober 2018 bedraagt
657.578.717
Nu: het volledig verwaterde aantal aandelen is 663,472,724
Die opties moeten op 31 januari gewoon zijn toegevoegd... anders kan het totaal aantal aandelen bij volledige verwatering niet zoveel toenemen.
Laatste datapunt dat we hebben zijn FY figs. The closing number of shares as at the reporting date was 621,501,238 (2016: 579,014,891). New issues of stock representing a total of 42,486,347 shares were made to investors during the year related to the conversion of the remaining Ordinary Bonds due 2021, exercise of warrants, and exercise of employee options. As at the date of this report, the fully diluted number of shares is 663,472,724 and the number of shares in issue is 622,002,770.
!_Professional_! schreef op 12 maart 2019 14:50 :
[...]
Laatste datapunt dat we hebben zijn FY figs.
The closing number of shares as at the reporting date was 621,501,238 (2016: 579,014,891). New issues of stock representing a total of 42,486,347 shares were made to investors during the year related to the conversion of the remaining Ordinary Bonds due 2021, exercise of warrants, and exercise of employee options. As at the date of this report, the fully diluted number of shares is 663,472,724 and the number of shares in issue is 622,002,770.
Geeft dus des te meer aan dat elke aandeelhouder wederom dilute.... 1 aandeel in 2016 is ~0.932 aandeel in 2017.
Lunten schreef op 12 maart 2019 14:47 :
Zalig zijn de simpelen van geest
Dan moet jij wel bijzonder zalig zijn..............
!_Professional_! schreef op 12 maart 2019 14:50 :
[...]
Laatste datapunt dat we hebben zijn FY figs.
The closing number of shares as at the reporting date was 621,501,238 (2016: 579,014,891). New issues of stock representing a total of 42,486,347 shares were made to investors during the year related to the conversion of the remaining Ordinary Bonds due 2021, exercise of warrants, and exercise of employee options.
As at the date of this report, the fully diluted number of shares is 663,472,724 and the number of shares in issue is 622,002,770.
Dus zo'n 6 mio stuks meer dan op 25 okt 2018. Hoe? ---> voornamelijk door de niet-aangemelde opties van 31 januari? (want dat zijn er al 2,4 + 1,44 + 1 = 4,84 mio.... plus nog wat bonussen in aandelen?)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)